Sino Biological,Inc. (SHE:301047)
China · Delayed Price · Currency is CNY 99.63
+6.32 (6.77%)
At close: Sep 8, 2026
Sino Biological,Inc. Revenue
Sino Biological,Inc. had revenue of 209.47M CNY in the quarter ending June 30, 2026, with 23.83% growth. This brings the company's revenue in the last twelve months to 768.00M, up 21.43% year-over-year. In the year 2025, Sino Biological,Inc. had annual revenue of 699.56M with 14.00% growth.
Revenue (ttm)
768.00M
Revenue Growth
+21.43%
P/S Ratio
15.78
Revenue / Employee
718.43K
Employees
1,069
Market Cap
12.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 699.56M | 85.89M | 14.00% |
| Dec 31, 2024 | 613.67M | -32.72M | -5.06% |
| Dec 31, 2023 | 646.39M | 71.79M | 12.49% |
| Jan 1, 2023 | 574.60M | -390.67M | -40.47% |
| Jan 1, 2022 | 965.27M | -631.02M | -39.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| Hualan Biological Vaccine | 1.19B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |